arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PMV Pharmaceuticals, Inc.

PMVP
$1.37 ▼ -0.14 (-9.27%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
32 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

PMV Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $73.1M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -26.4% ↘
FCF / Share $-0.27 ↗
Trailing P/E —
Price / Book 1.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-18.04M
↓ -3.5% —
FCF / Share Free cash flow per share
$-0.27
↑ +26.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
12
Cash Quality ↑
63

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 32 quarters